MXene Pharmaceutical Composition for Gut Flora and Butyrate Enhancement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies do not effectively address the improvement of intestinal bacterial flora or the increase of short-chain fatty acids, which are crucial for treating and preventing various diseases, particularly those related to intestinal and blood-brain barrier permeability and hypertension.
Innovation Solution
A pharmaceutical composition comprising MXene, a layered material, is used to promote the proliferation of intestinal bacteria, thereby increasing the production of short-chain fatty acids such as butyric acid, which can repair blood vessel barriers and lower blood pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If genetically engineered E. coli is administered to promote Ruminococcaceae proliferation, then butyric acid production increases, but the complexity of the treatment and potential safety concerns increase
Solution Approach 1:
The patent extracts and utilizes MXene as a key component that can be administered separately to achieve the desired effect of promoting Ruminococcaceae proliferation and butyric acid production without the need for complex genetically engineered E. coli formulations
Solution Approach 2:
The patent changes the approach from using genetically engineered organisms to using MXene material with specific properties (layered structure, surface area, chemical composition) to achieve the same therapeutic effect through material parameter optimization rather than biological engineering
2Reliability
If diversity of intestinal bacteria is promoted to enhance butyric acid production, then blood-brain barrier permeability is reduced, but the mechanism is not fully understood and treatment is complex
Solution Approach 1:
The patent introduces MXene as an intermediary substance that mediates the effect on intestinal bacteria and subsequently on blood-brain barrier integrity, providing a clearer mechanism where MXene promotes Ruminococcaceae proliferation which then produces butyric acid that repairs the blood-brain barrier
Solution Approach 2:
The patent optimizes specific parameters of MXene (layered structure, surface area, chemical composition) to enhance its ability to promote beneficial bacterial growth and butyric acid production, thereby improving blood-brain barrier integrity through controlled material properties
3Quantity of substance
If butyric acid production is enhanced to correct hypertensive symptoms, then blood pressure is ameliorated, but the treatment mechanism is complex and not fully understood
Solution Approach 1:
The patent extracts and utilizes MXene as a direct treatment agent that can be administered to achieve butyric acid production and blood pressure amelioration without the need for complex genetically engineered organisms or multiple treatment steps
Solution Approach 2:
The patent optimizes MXene material parameters (layered structure, surface area, chemical composition) to maximize its effectiveness in promoting butyric acid production and correcting hypertensive symptoms through a simplified treatment pathway
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MXene composition enhances intestinal bacterial flora, increases short-chain fatty acid production, and provides therapeutic benefits by repairing blood vessel barriers, reducing permeability, and ameliorating hypertension, offering potential treatments for diseases like vascular dementia and inflammatory bowel disease.
Implementation Method 1
MXene can promote the proliferation of intestinal bacteria
Implementation Method 2
the production of Butyric acid can be enhanced
Implementation Method 3
Butyric acid, which may be produced thereby, will contribute to the suppression of permeability enhancement in Blood Brain Barrier (BBB)
Data Source
AI summary
The present disclosure provides novel pharmaceutical compositions, e.g., a pharmaceutical composition capable of improving the intestinal bacterial flora in vivo or increasing a short-chain fatty acid in vivo, which comprises MXene. Methods of treatment using such compositions are also provided.